Open AccessChimeric antibody receptors (CARs): Driving T-cell specificity to enhance anti-tumor immunity
Author(s) -
Partow Kebriaei,
Susan S. Kelly,
Pallavi R. Manuri,
Bipulendu Jena,
Rineka Jackson,
Elizabeth J. Shpall,
Richard E. Champlin,
Laurence J.N. Cooper
Publication year - 2012
Publication title -
frontiers in bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.606
H-Index - 46
eISSN - 1944-7906
pISSN - 1945-0516
DOI - 10.2741/282
Subject(s) - chimeric antigen receptor , immune system , antigen , adoptive cell transfer , acquired immune system , antibody , immunology , receptor , t cell receptor , immunity , t cell , cancer research , biology , genetics
Adoptive transfer of antigen-specific T cells is a compelling tool to treat cancer. To overcome issues of immune tolerance which limits the endogenous adaptive immune response to tumor-associated antigens, robust systems for the genetic modification and characterization of T cells expressing chimeric antigen receptors (CARs) to redirect specificity have been produced. Refinements with regards to persistence and trafficking of the genetically modified T cells are underway to help improve the potency of genetically modified T cells. Clinical trials utilizing this technology demonstrate feasibility, and increasingly, antitumor activity, paving the way for multi-center trials to establish the efficacy of this novel T-cell therapy.